{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T00:10:59Z","timestamp":1783210259946,"version":"3.54.6"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"PMG","award":["R01 DA041298"],"award-info":[{"award-number":["R01 DA041298"]}]},{"name":"SNK","award":["K01 DA048172"],"award-info":[{"award-number":["K01 DA048172"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>The main mode of transmission of Hepatitis C in North America is through injection drug use. Availability of accessible care for people who inject drugs is crucial for achieving hepatitis C elimination.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Objective<\/jats:title>\n<jats:p>The objective of this analysis is to compare the changes in injection drug use frequency and high-risk injection behaviors in participants who were randomized to accessible hepatitis c care versus usual hepatitis c care.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Participants who were hepatitis C virus RNA positive and had injected drugs in the last 90 days were enrolled and randomized 1:1 to an on-site, low threshold accessible care arm or a standard, referral-based usual care arm. Participants attended follow-up appointments at 3, 6, 9, and 12 months during which they answered questions regarding injection drug use frequency, behaviors, and treatment for opioid use disorder.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Primary outcomes<\/jats:title>\n<jats:p>The primary outcomes of this secondary analysis are the changes in the frequency of injection drug use, high-risk injection behaviors, and receiving medication for opioid use disorder in the last 30 days.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec005\">\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 165 participants were enrolled in the study, with 82 participants in the accessible care arm and 83 participants in the usual care arm. Participants in the accessible care arm were found to have a statistically significant higher likelihood of reporting a lower range of injection days (accessible care-by-time effect OR = 0.78, 95% CI = 0.62\u20130.98) and injection events (accessible care-by-time effect OR = 0.70, 95% CI = 0.56\u20130.88) in the last 30 days at a follow-up interview relative to those in the usual care arm. There were no statistically significant differences in the rates of decrease in receptive sharing of injection equipment or in the percentage of participants receiving treatment for opioid use disorders in the two arms.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec006\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Hepatitis C treatment through an accessible care model resulted in statistically higher rates of decrease in injection drug use frequency in people who inject drugs.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0308102","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T18:25:52Z","timestamp":1724955952000},"page":"e0308102","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Reduced injection risk behavior with co-located hepatitis C treatment at a syringe service program: The accessible care model"],"prefix":"10.1371","volume":"19","author":[{"given":"Claire So Jeong","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Mateu-Gelabert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yesenia Aponte","family":"Melendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunki","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6363-2839","authenticated-orcid":true,"given":"Shashi N.","family":"Kapadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen M.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2846-9762","authenticated-orcid":true,"given":"Benjamin","family":"Eckhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,8,29]]},"reference":[{"issue":"10049","key":"pone.0308102.ref001","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","article-title":"The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013.","volume":"388","author":"JD Stanaway","year":"2016","journal-title":"The Lancet"},{"issue":"10348","key":"pone.0308102.ref002","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0140-6736(22)01377-0","article-title":"Viral hepatitis elimination: a challenge, but within reach","volume":"400","author":"The Lancet","year":"2022","journal-title":"The Lancet"},{"issue":"4","key":"pone.0308102.ref003","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3961\/jpmph.21.151","article-title":"Trends of the Global Hepatitis C Disease Burden: Strategies to Achieve Elimination","volume":"54","author":"N Brunner","year":"2021","journal-title":"Journal of Preventive Medicine and Public Health"},{"issue":"5B","key":"pone.0308102.ref004","doi-asserted-by":"crossref","first-page":"s30","DOI":"10.1053\/jhep.2002.36791","article-title":"The burden of hepatitis C in the United States","volume":"36","author":"WR Kim","year":"2002","journal-title":"Hepatology"},{"key":"pone.0308102.ref005","year":"2022","journal-title":"Viral Hepatitis Surveillance Report 2019"},{"issue":"3","key":"pone.0308102.ref006","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.30297","article-title":"Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013\u20102016.","volume":"69","author":"MG Hofmeister","year":"2019","journal-title":"Hepatology"},{"issue":"5","key":"pone.0308102.ref007","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/cid\/ciaa142","article-title":"Modeling Combination Hepatitis C Virus Treatment and Prevention Strategies in a Network of People Who Inject Drugs in the United States","volume":"72","author":"A Zelenev","year":"2021","journal-title":"Clinical Infectious Diseases"},{"key":"pone.0308102.ref008","author":"Centers for Disease Control and Prevention","year":"2023","journal-title":"Viral Hepatitis Surveillance Report\u2013United States, 2023."},{"issue":"5","key":"pone.0308102.ref009","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1001\/jamainternmed.2022.0170","article-title":"Accessible Hepatitis C Care for People Who Inject Drugs.","volume":"182","author":"B Eckhardt","year":"2022","journal-title":"JAMA Intern Med"},{"issue":"Supplement_5","key":"pone.0308102.ref010","doi-asserted-by":"crossref","first-page":"S392","DOI":"10.1093\/infdis\/jiaa142","article-title":"Psychosocial Factors and the Care Cascade for Hepatitis C Treatment Colocated at a Syringe Service Program","volume":"222","author":"D Winetsky","year":"2020","journal-title":"J Infect Dis"},{"key":"pone.0308102.ref011","doi-asserted-by":"crossref","first-page":"108589","DOI":"10.1016\/j.drugalcdep.2021.108589","article-title":"Medical provider stigma experienced by people who use drugs (MPS-PWUD): Development and validation of a scale among people who currently inject drugs in New York City.","volume":"221","author":"C Fong","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"9","key":"pone.0308102.ref012","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3109\/10826084.2016.1161054","article-title":"Clinicians\u2019 Views of Hepatitis C Virus Treatment Candidacy With Direct-Acting Antiviral Regimens for People Who Inject Drugs.","volume":"51","author":"AK Asher","year":"2016","journal-title":"Subst Use Misuse."},{"key":"pone.0308102.ref013","doi-asserted-by":"crossref","first-page":"103247","DOI":"10.1016\/j.drugpo.2021.103247","article-title":"Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: A knowledge synthesis.","volume":"96","author":"A Amoako","year":"2021","journal-title":"International Journal of Drug Policy"},{"issue":"1","key":"pone.0308102.ref014","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/cld.925","article-title":"The Current Status of US and Global Access to Direct\u2010Acting Antiviral Regimens for Hepatitis C Virus Infection.","volume":"16","author":"CS Graham","year":"2020","journal-title":"Clin Liver Dis (Hoboken)."},{"key":"pone.0308102.ref015","year":"2023","journal-title":"Center for Health Law and Policy Innovation & National Viral Hepatitis Roundtable, Hepatitis C: State of Medicaid Access (2023)."},{"key":"pone.0308102.ref016","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.drugpo.2019.05.011","article-title":"Impact of Hepatitis C treatment on behavioural change in relation to drug use in people who inject drugs: A systematic review.","volume":"72","author":"M Caven","year":"2019","journal-title":"International Journal of Drug Policy"},{"issue":"1","key":"pone.0308102.ref017","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/ADM.0000000000000739","article-title":"Retention Strategies for Medications for Opioid Use Disorder in Adults: A Rapid Evidence Review.","volume":"15","author":"B Chan","year":"2021","journal-title":"J Addict Med."},{"key":"pone.0308102.ref018","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.drugpo.2019.01.012","article-title":"Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs","volume":"66","author":"E Day","year":"2019","journal-title":"International Journal of Drug Policy"},{"issue":"4","key":"pone.0308102.ref019","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy048","article-title":"Hepatitis C Treatment Outcomes for People Who Inject Drugs Treated in an Accessible Care Program Located at a Syringe Service Program.","volume":"5","author":"BJ Eckhardt","year":"2018","journal-title":"Open Forum Infect Dis."},{"key":"pone.0308102.ref020","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.drugalcdep.2015.06.007","article-title":"\u201cHepatitis C treatment turned me around:\u201d Psychological and behavioral transformation related to hepatitis C treatment.","volume":"153","author":"AW Batchelder","year":"2015","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"pone.0308102.ref021","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1521\/aeap.2014.26.2.144","article-title":"The Staying Safe Intervention: Training People Who Inject Drugs in Strategies to Avoid Injection-Related HCV and HIV Infection","volume":"26","author":"P Mateu-Gelabert","year":"2014","journal-title":"AIDS Education and Prevention"},{"key":"pone.0308102.ref022","doi-asserted-by":"crossref","DOI":"10.1002\/9781119013563","volume-title":"Statistical Analysis with Missing Data","author":"RJA Little","year":"2002"},{"issue":"14","key":"pone.0308102.ref023","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1097\/QAD.0b013e32823f9066","article-title":"A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users","volume":"21","author":"RS Garfein","year":"2007","journal-title":"AIDS"},{"issue":"5","key":"pone.0308102.ref024","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/add.12867","article-title":"Randomized controlled trial of motivational interviewing for reducing injection risk behaviours among people who inject drugs.","volume":"110","author":"K Bertrand","year":"2015","journal-title":"Addiction"},{"issue":"1","key":"pone.0308102.ref025","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12954-020-00399-8","article-title":"\u201cThey look at us like junkies\u201d: influences of drug use stigma on the healthcare engagement of people who inject drugs in New York City.","volume":"17","author":"B Muncan","year":"2020","journal-title":"Harm Reduct J."},{"key":"pone.0308102.ref026","first-page":"161","volume":"47","author":"M. Harris","year":"2017","journal-title":"Managing expense and expectation in a treatment revolution: Problematizing prioritisation through an exploration of hepatitis C treatment \u2018benefit.\u2019 International Journal of Drug Policy"},{"issue":"1","key":"pone.0308102.ref027","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","article-title":"Retention in medication-assisted treatment for opiate dependence: A systematic review.","volume":"35","author":"C Timko","year":"2016","journal-title":"J Addict Dis."},{"issue":"1","key":"pone.0308102.ref028","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/epirev\/mxaa001","article-title":"Adherence to and Retention in Medications for Opioid Use Disorder Among Adolescents and Young Adults.","volume":"42","author":"A Viera","year":"2020","journal-title":"Epidemiol Rev."},{"issue":"1","key":"pone.0308102.ref029","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12954-021-00568-3","article-title":"The impact of COVID-19 on people who inject drugs in New York City: increased risk and decreased access to services.","volume":"18","author":"Y Aponte-Melendez","year":"2021","journal-title":"Harm Reduct J."},{"issue":"2","key":"pone.0308102.ref030","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases\u2013Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.","volume":"71","author":"MG Ghany","year":"2020","journal-title":"Hepatology"},{"issue":"suppl_2","key":"pone.0308102.ref031","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1093\/cid\/cit306","article-title":"Treatment of Hepatitis C Virus Infection Among People Who Are Actively Injecting Drugs: A Systematic Review and Meta-analysis","volume":"57","author":"EJ Aspinall","year":"2013","journal-title":"Clinical Infectious Diseases"},{"issue":"1","key":"pone.0308102.ref032","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000049487","article-title":"Treatment of Chronic Hepatitis C in Injecting Drug Users: 5 Years\u2019 Follow-Up.","volume":"8","author":"O Dalgard","year":"2002","journal-title":"Eur Addict Res."},{"issue":"4","key":"pone.0308102.ref033","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jhep.2019.11.012","article-title":"Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis","volume":"72","author":"B Hajarizadeh","year":"2020","journal-title":"J Hepatol"},{"issue":"1\u20132","key":"pone.0308102.ref034","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.drugalcdep.2007.09.011","article-title":"A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus","volume":"93","author":"SL Currie","year":"2008","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"pone.0308102.ref035","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.drugpo.2007.04.004","article-title":"Global estimates of prevalence of HCV infection among injecting drug users","volume":"18","author":"C Aceijas","year":"2007","journal-title":"International Journal of Drug Policy"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0308102","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T18:26:22Z","timestamp":1724955982000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0308102"}},"subtitle":[],"editor":[{"given":"Jason T.","family":"Blackard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,8,29]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0308102","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,29]]}}}